Neuphoria Therapeutics Inc (NEUP)vsRevolution Medicines Inc (RVMD)
NEUP
Neuphoria Therapeutics Inc
$3.36
-0.88%
HEALTHCARE · Cap: $18.61M
RVMD
Revolution Medicines Inc
$190.27
+0.82%
HEALTHCARE · Cap: $38.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Neuphoria Therapeutics Inc generates 58% more annual revenue ($1.17M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. NEUP earns a higher WallStSmart Score of 28/100 (F).
NEUP
Avoid28
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 15.6x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : NEUP
The strongest argument for NEUP centers on Price/Book, Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : NEUP
The primary concerns for NEUP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
NEUP is growing revenue faster at 0.0% — sustainability is the question.
NEUP generates stronger free cash flow (1M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NEUP scores higher overall (28/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neuphoria Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neuphoria Therapeutics Inc (Ticker: NEUP) is a groundbreaking biotechnology firm focused on revolutionizing mental health disorders treatment via psychedelic compounds and advanced drug delivery systems. The company boasts a promising pipeline of preclinical candidates, strategically targeting significant unmet needs within the mental healthcare sector, coinciding with the increasing acceptance of alternative therapies. As a frontrunner in the rapidly evolving psychedelic therapy market, Neuphoria offers a compelling investment proposition for institutional investors keen on supporting innovative solutions that may fundamentally alter the landscape of mental health treatment.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?